Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022

Serology studies also showed that all doses of deucravacitinib decreased levels of anti-double stranded DNA, bringing them closer to baseline. Complement numbers also returned toward normal in patients who had abnormally low levels at treatment initiation. Additionally, treatment with deucravacitinib at all doses suppressed production of interferon and cytokines and chemokines downstream of interferon activity, while also suppressing markers associated with B cell activation and differentiation.^10,15

Dr. Pike concluded, “We feel that deucravacitinib shows promise as a novel therapy for SLE and warrants further investigation in phase 3 trials.”

Ruth Jessen Hickman, MD, is a graduate of the Indiana University School of Medicine. She is a freelance medical and science writer living in Bloomington, Ind.

References

1. Dörner T, Szanto A, Tseng J. Remibrutinib (LOU064) in Sjögren’s syndrome: Safety and efficacy results from a 24-week placebo-controlled proof-of-concept study. Arthritis Rheumatol. 2022; 74(suppl 9).
2. Negrini S, Emmi G, Greco M, et al. Sjögren’s syndrome: A systemic autoimmune disease. Clin Exp Med. 2022 Feb;22(1):9–25.
3. Gabizon R, London N. A fast and clean BTK inhibitor. J Med Chem. 2020 May 28;63(10):5100–5101.
4. Giudice V, Vecchione C, Selleri C. Cardiotoxicity of novel targeted hematological therapies. Life (Basel). 2020 Dec 11;10(12):344.
5. Geladaris A, Torke S, Weber MS. Bruton’s tyrosine kinase inhibitors in multiple sclerosis: Pioneering the path towards treatment of progression? CNS Drugs. 2022 Oct;36(10):1019-1030.
6. Maurer M, Berger W, Giménez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. 2022 Sep 9;S0091-6749(22)01181-2.
7. Ohmura K. Which is the best SLE activity index for clinical trials? Mod Rheumatol. 2021 Jan;31(1):20–28.
8. Cooper C, Wratten S, Williams-Hall R, et al. Qualitative research with patients and physicians to assess content validity and meaningful change on ESSDAI and ESSPRI in Sjögren’s. Rheumatol Ther. 2022 Dec;9(6):1499–1515.
9. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren’s syndrome treated with rituximab. Ann Rheum Dis. 2012 Aug;71(8):1297–1302.
10. Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2022 Nov 11. doi: 10.1002/art.42391. Epub ahead of print.
11. Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 Jun;81(6):815–822.
12. Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb). 2021 Oct;11(5):1763–1776.
13. Ohmura K. Which is the best SLE activity index for clinical trials? Mod Rheumatol. 2021 Jan;31(1):20–28.
14. Mucke J, Alarcon-Riquelme M, Andersen J, et al. What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. Lupus Sci Med. 2021 May;8(1):e000506.
15. Kahlenber JM, Sanz I, Wu C, et al. Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: Pharmacodynamic analysis from the phase 2 PAISLEY study. Arthritis Rheumatol. 2022;74(suppl 9).